HRAS Antibody (Y132)

Product Discontinued

HRAS Antibody (Y132) Summary

• Immunogen: A synthetic peptide corresponding to residues in the C-terminus of human H-Ras was used as an immunogen.
• Specificity: The antibody does not cross-react with other Ras family member.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: HRAS
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:100
  • Immunocytochemistry/ Immunofluorescence 1:100-250
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation 1:50
  • Western Blot 1:500-1000
• Theoretical MW: 21 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Predicted to work with: Chicken

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 49% PBS, 0.05% BSA and 50% Glycerol
• Preservative: 0.01% Sodium Azide
• Purity: Protein A purified

Notes

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Alternate Names for HRAS Antibody (Y132)

• C-BAS/HAS;C-HA-RAS1;C-H-RAS;CTLO;GTPase HRas;HAMSV;HRAS1;H-RASIDX;p21ras;RASH1

Background

Ras, a signal transducer, was first characterized as the transforming genes of Harvey & Kristen sarcoma virus (1). The Ras family (H-Ras, N-Ras, and K-Ras) regulates cell growth, differentiation and apoptosis (2). Switching from an active or resting state, Ras can either bind GTP or GDP respectively. In the triphosphate conformation, Ras will interact with GTPase activating protein (GAP) to increase its activity (3). Mutations in any of the three isoforms can convert these proteins into active oncogenes. Additionally, Ras mutations are found in 30 % of all human cancer (4).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for vH RAS Antibody (NB110-57027)(4)

Publications using NB110-57027

• Jha SK, Rauniyar K, Chronowska E et al. SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors Mol. Cancer Ther. 2019-05-08 [PMID: 31068384] (WB)
• Rimessi A, Marchi S, Patergnani S, Pinton P. H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling. Oncogene 2013-06-03 [PMID: 23728347] (WB, Mouse)
• Kawasaki K, Watabe T, Sase H et al. Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells. J Cell Biol 2008-04-01 [PMID: 18391074] (IF/IHC)
• Swarbrick A, Roy E, Allen T et al. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci U S A. 2008-04-01 [PMID: 18378907]

Bioinformatics

• Gene Symbol: HRAS
• Entrez:
  • 3265(Human)
  • 15461(Mouse)
  • 293621(Rat)
• Uniprot:
  • P01112(Human)